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introduction: Acute renal failure (ARF) has a poor prognosis in patients with cancer 
requiring intensive care unit (ICU) admission. Our aim is finding prognostic factors 
for hospital mortality in patients with cancer with ARF requiring renal replacement 
therapy (RRT).
Methods: In this retrospective study, all patients with cancer with ARF treated with con-
tinuous venovenous filtration (CVVHDF) in the ICU of the Institut Jules Bordet, between 
January 1, 2003 and December 31, 2012, were included.
results: One hundred and three patients are assessed: men/women 69/34, median 
age 62 years, solid/hematologic tumors 68/35, median SAPS II 56. Mortality rate was 
63%. Seven patients required chronic renal dialysis. After multivariate analysis, two 
variables were statistically associated with hospital mortality: more than one organ 
failure (including kidney) (OR 5.918; 95% CI 2.184–16.038; p < 0.001) and low albumin 
level (OR 3.341; 95% CI 1.229–9.077; p = 0.02). Only minor complications related to 
CVVHDF have been documented.
conclusion: Despite the poor prognosis associated with ARF, CVVHDF is an effective 
and tolerable renal replacement technique in patients with cancer admitted to the ICU. 
Multiple organ failure and hypoalbuminemia, two independent prognostic factors for 
hospital mortality have to be considered when deciding for introducing RRT.
Keywords: intensive care, neoplasms, acute kidney injury, renal dialysis, prognosis
inTrODUcTiOn
Acute renal failure (ARF) is a frequent complication in patients with cancer. It may develop due to the 
cancer itself (multiple myeloma, neoplastic urinary tract obstruction, renal malignant infiltration), 
its treatment (nephrotoxic chemotherapy, tumor lysis syndrome …), or secondary complication 
(sepsis, nephrotoxic antibiotics, iodine contrast administration …) (1, 2). Up to 54% of patients with 
cancer admitted to the intensive care unit (ICU) develop ARF and some require renal replacement 
therapy (RRT) (3–5). Despite improvements in the general management of ICU patients with cancer, 
ARF worsens the prognosis. In patient with cancer requiring dialysis, hospital mortality rates are 
reported between 51 and 90% (6–8).
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A few published studies are dealing with outcome of patients 
with cancer with ARF, who required RRT. Results are difficult 
to compare for several reasons as types and indications of RRT 
largely varying from one study to another or populations are not 
comparable. For example, the proportion of solid and hemato-
logic tumors and the number of hematological transplantation 
were inconstant across the studies while these patients are carry-
ing very distinct prognosis (7–14).
In a first study performed at the Bordet Institute, continuous 
venovenous hemodiafiltration (CVVHDF) was shown effective 
for the treatment of ARF in patients with cancer, including 
solid and hematologic tumors as well as auto- and allograft 
recipients (15). In the latter small retrospective study, the single 
independent poor prognostic factor for hospital mortality was 
the increasing number of organ failures. In another study with 
a similar case-mix, other authors confirmed the prognostic 
role of the number of organ failures on hospital mortality (16). 
As dialysis techniques evolve with time, we aimed at confirming 
our previously published results on the effectiveness of RRT in 
a larger cohort of patients with cancer. The primary objective of 
this retrospective study was the search of prognostic factors for 
hospital mortality in this group of patients that could eventually 
help in guiding decision of RRT.
PaTienTs anD MeThODs
All consecutive patients admitted in the medical ICU of the 
Institut Jules Bordet between January 1, 2003 and December 
31, 2012 were recorded. The records of the patients with ARF 
requiring continuous venovenous RRT at admission or during 
ICU stay were retrospectively reviewed. Only the first episode of 
ARF requiring RRT was taken into account. Patients with end-
stage renal diseases requiring chronic dialysis were excluded. 
The study was approved by the ethical committee of the Institut 
Jules Bordet.
Acute renal failure was defined as a creatinine increase 
>2 mg/dl (176 μmol/l) in case of pre-existing normal value, or 
an increase >1  mg/dl from the basic value in case of chronic 
renal failure. Decision for CVVHDF was based on one (or more) 
of the following characteristics: bicarbonate level <10  mg/dl, 
metabolic acidosis (pH <7.30), uremia >33.2 mmol/l, kaliemia 
>6  mEq/dl, water overload, pericarditis secondary to ARF, 
uremic encephalitis, severe ionic abnormalities (hyponatremia, 
hyperphosphoremia), oligoanuria in presence of evolutive ARF.
The following clinical data were retrieved from the patient’s 
charts: gender, age, type of cancer, cancer phase (17) (diagnostic, 
curative, controllable but no more curable, pivotal or palliative), 
cancer status (18) (disease under induction therapy, complete 
remission without or on active anti-cancer treatment, partial 
remission, stable disease, progression), reason for ICU admission, 
anticancer treatments including bone marrow transplantation, 
potential nephrotoxic agents (iodine contrast agent, antibiotics, 
chemotherapy  …), co-morbidities, ARF etiology, reason for 
CVVHDF, variables used for the computation of Simplified Acute 
Physiology Score II (SAPS II) (19).
The following data were collected at start of RRT: furosemide 
and vasopressive drugs administration, diuresis, blood pressure, 
heart and respiratory rates, temperature, biological variables, 
number of organ failures (including renal failure) at the time 
of ARF, the immunosuppression status according to the Organ 
Dysfunction and/or Infection (ODIN) score, the presence of an 
acute respiratory distress syndrome, and mechanical ventilation 
support.
We also recorded the main characteristics of RRT: duration, 
CVVHDF parameters, CVVHDF complications. To determine 
the final outcome of the patient, we assessed the renal function 
status (complete, partial or absence of return to initial creatinine 
values), mortality rates (during hospital and ICU stays), the date 
and cause of death, or last date known to be alive.
statistics and Data analysis
Results are reported as medians and range. Prognostic factors 
for hospital mortality were tested in univariate analysis. Binary 
variables were compared by chi-square test or Fischer’s exact 
test. Non-parametric Mann–Whitney tests were used to compare 
continuous variables. Variables yielding p value less or equal to 
0.2 in univariate analysis were entered into a multiple logistic 
regression. A Hosmer–Lemeshow test was performed to verify 
the goodness of fit. A p value <0.05 was considered statistically 
significant.
resUlTs
One-hundred and twelve patients were treated with RRT during 
the study period. One patient on chronic dialysis was excluded. 
Incomplete charts led to exclusion of a further 8 cases leaving 103 
patients assessable for the final analysis.
The principal characteristics of the population are reported 
in Table 1. Renal failure primarily of renal origin, occurred in 
83 patients, obstructive renal failure in 1 patient and both types 
combined in 19 patients. Etiologies of renal failure from renal ori-
gin were miscellaneous and detailed in Table 2. A  combination 
of nephrotoxic insults was observed in 43 patients (42%). 
A  number  of potentially nephrotoxic drugs were implicated 
in the development of renal failure: antibiotics/antifungals/
antivirals (n =  45), non-steroidal anti-inflammatory (n =  15), 
iodine contrast product (n = 15), chemotherapy agents (n = 12), 
furosemide (dose ≥500 mg/24 h) (n = 10), ciclosporine/sirolimus 
(n =  9), sartan/ACE inhibitor (n =  4), zoledronic acid/OKT3 
(n = 2). A combination of nephrotoxics was found in 31 cases.
Criteria to initiate RRT were as follow: blood pH <7.3 (n = 28), 
(oligo)anuria (n = 17), uremia (n = 7), severe ionic abnormality 
(n = 6), water overload (n = 3), uremic encephalitis (n = 1), or 
a combination of these factors (n = 40). In one case, the precise 
indication for CVVHDF can not be retrospectively determined.
cVVhDF Therapy Outcomes
Extra-renal replacement therapy was CVVHDF in 100 patients, 
CVVH (continuous veno-venous hemofiltration) and CVVD 
(continuous veno-venous dialysis) in 1 and 2 cases, respectively. 
Pre-dilution technique was applied in 54 cases, post-dilution in 35 
cases and alternatively both in 12 cases. Median blood flow rate 
was 180 ml/min (range: 60–200). Median reinjection fluid rate 
was 28.6 ml/kg/h. The median cumulated overall hemofiltration 
TaBle 2 | Principal etiologies of acute renal failure in patients admitted 
in the icU.
n %a
Nephrotoxic drugs 48 47
Shock/sepsis 41 40
Acute tubular necrosisb 19 18
Cancer 10 10
Tumor lysis syndrome 8 8
MOF 4 4
Hepato-renal syndrome 4 4
Other 12 12
Unknownc 6 6
aOne patient could have had more than one etiological factor: a combination of at least 
two factors has been seen in 43 patients (42% of the cases).
bAcute tubular necrosis except nephrotoxic drugs and shock/sepsis.
cNo aetiology has been formally identified.
MOF, multiple organ failure.
TaBle 1 | characteristics at icU admission of 103 patients with cancer 
with acute renal failure requiring renal replacement therapy.
Sex (male/female) 69/34 (67%/33%)
Age (median/range) 62 years (19–87)
Solid malignancies (locoregional/metastatic) 68 (66%) (28/40)
Breast 7 (7%)
Lung 6 (6%)
Digestive tract 15 (15%)
Prostate/bladder/kidney 23 (22%)
Other 17 (17%)
Hematological malignancies 35 (34%)
Leukemia 10 (10%)
Lymphoma 14 (14%)
Multiple myeloma 9 (9%)
Myelodysplastic syndrome 2 (2%)
Stem cell transplantation before ICU admission (allo/auto) 18 (14/4) (17%)
Cancer phase
Diagnostic 9 (9%)
Curative 41 (40%)
Controllable 53 (51%)
Cancer status
Induction 25 (24%)
Diagnostic 9 (9%)
Remission (partial or complete) 35 (34%)
Stabilization 1 (1%)
Progression 33 (32%)
Causes of ICU admission
Renal disease 58 (56%)
Shock/sepsis 20 (19%)
Metabolic disorder 9 (9%)
Respiratory failure 8 (8%)
Other 8 (8%)
Chemotherapy given before ICU admission
Less than 15 days 35 (34%)
More than 15 days 27 (26%)
No 41 (40%)
Immunodepression 50 (49%)
Urinary tract infection 14 (14%)
Diabetes 14 (14%)
Baseline characteristics at the time of initiation of CVVHDF
ARDS 25 (24%)
Mechanical ventilation 53 (51%)
Vasopressors 43 (42%)
Hematological failure 28 (27%)
>1 organ failure 65 (63%)
pH (median/range) 7.3 (7.02–7.52)
Natremia (mEq/l) (median/range) 138 (122–150)
Kaliemia (mEq/l) (median/range) 4.7 (2.9–8)
Creatininemia (mg/dl) (median/range) 3.76 (1.28–20.1)
Uremia (mg/dl) (median/range) 151 (49–492)
SAPS II (median/range) 56 (28–99)
ICU, intensive care unit; SAPS, simplified acute physiology score; allo, allogenic; auto, 
autologous; ARDS, acute respiratory distress syndrome.
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duration was 34.5  h (range: 2–354  h). Complications of RRT 
were filter coagulation at least once (n  =  32), hypotension 
(n = 3) and uncomplicated hemorrhage at the catheter insertion’s 
site (n = 3).
Complete or partial (persistent abnormal creatinine value not 
requiring further RRT) ARF resolution was observed in 27 and 
18 patients, respectively. No resolution, defined as required RRT 
at the time of death (n = 49), transfer in another hospital without 
ARF resolution (n = 2), or need for chronic dialysis (n = 7), was 
found in 58 patients.
Patient survival Outcomes
Among patients alive at hospital discharge, complete, partial, or 
absence of ARF resolution was observed in 20, 9, and 9 patients, 
respectively. Seven patients (18% of the patients alive at the hospi-
tal discharge) needed chronic dialysis. Of them, 2 had a multiple 
myeloma and 5 patients presented with a loco-regional (n = 3) 
or metastatic (n = 2) solid tumor. Five of them had prior renal 
disease: polycystic kidney (n = 2), myelomatous kidney (n = 1), 
or a chronic renal failure not requiring dialysis (n = 2).
The median duration of ICU and hospital stays were 9 days 
(range: 1–124  days) and 22  days (range: 1–155  days). Fifty 
patients died in the ICU and a further 15 in the general ward after 
ICU discharge. Thirty-eight patients were discharged alive from 
the hospital. The ICU mortality rate was 49% and the hospital 
mortality rate was 63%. The main causes of hospital death were 
multiple organ failure (n = 21), septic shock (n = 16), shock from 
another origin (n = 7), cancer (n = 6), ARF (n = 2).
Univariate analysis of prognostic factors for hospital mortality 
is reported in Table 3. All significant variables and those with a 
p-value <0.2 in univariate analysis were included in a multivariate 
analysis. Two variables were statistically independent pejorative 
prognostic factors for hospital mortality in multivariate analysis: 
the number of organ failure [Odds ratio = 5.918; 95% confidence 
interval (CI) 2.184–16.038; p <  0.001] and hypoalbuminemia 
(Odds ratio = 3.341; 95% CI 1.229–9.077; p = 0.02).
At the time of analysis, 90 patients died, and 3 patients were 
lost to follow up. Median survival of patients discharged alive 
from hospital was 413  days; it was 157  days for patients on 
chronic dialysis but 441 days for those independent from dialysis 
(p = 0.34).
DiscUssiOn
In this retrospective study including patients with cancer with 
ARF requiring RRT, two statistically significant independent 
prognostic factors for hospital mortality were identified. A higher 
risk of death was associated with increasing number of organ 
failures and with low albumin levels. Cancer characteristics and 
SAPS II score were not associated with outcome.
TaBle 3 | Prognostic factors for hospital mortality – univariate analysis.
non-survivors survivors p-value
Hematological tumor 27 (77%) 8 (23%)
Solid tumor 38 (55%) 30 (45%) 0.034
Age (median) 61 years 64 years 0.06
Number of organ failure
1 10 (29%) 24 (71%) <0.00001
>1 55 (80%) 14 (20%)
Cancer status
Progression 22 (67%) 11 (33%) 0.60
Other than progression 43 (61%) 27 (39%)
Cancer phase
Diagnostic 6 (67%) 3 (33%) 0.23
Curative 21 (51%) 20 (49%)
Controllable 38 (72%) 15 (28%)
Immunodepression No 29 (55%) 24 (45%) 0.07
Yes 36 (72%) 14 (28%)
ARF origin Renal 51 (61%) 32 (39%) 0.43
Mixed 13 (68%) 6 (32%)
Allo/auto graft No 49 (58%) 36 (42%) 0.01
Yes 16 (89%) 2 (11%)
ARDS No 47 (56%) 37 (44%) 0.001
Yes 18 (95%) 1 (5%)
Mechanical 
ventilation
No 22 (44%) 28 (56%) 0.0001
Yes 43 (81%) 10 (19%)
Vasopressor No 30 (50%) 30 (50%) 0.002
Yes 35 (81%) 8 (19%)
Median (range) Median (range)
SAPS II 57 (28–99) 50 (26–88) 0.022
Bilirubinemia (mg/dl) 1.4 (0.2–19) 0.5 (0.1–5.7) 0.0002
Creatininemia (mg/dl) 3.6 (1.3–18) 4.8 (1.3–20) 0.02
Uremia (mg/dl) 147 (55–492) 154 (49–485) 0.78
Natremia (mEq/l) 139 (122–150) 135 (128–148) 0.01
Kaliemia (mEq/l) 4.7 (3.2–8) 4.5 (2.9–7.8) 0.33
Phosphatemia (mEq/l) 6.2 (2.9–11.3) 6.1 (2.6–14.6) 0.80
Bicarbonate (mEq/l) 19 (6–32) 19 (3–27) 0.64
INR 1.45 (0.97–3.9) 1.33 (0.8–2.9) 0.15
Albuminemia (g/dl) 2.5 (0.7–4) 3.05 (1.7–5.1) 0.0001
Leukocytes (103/mm3) 7.8 (0.02–39) 13 (0.05–50) 0.07
SAPS, Simplified acute physiology score; INR, international normalized ratio; ARF, acute 
kidney injury; ARDS, acute respiratory distress syndrome.
Bold font highlight the significant variables in univariate analysis.
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This study confirms that CVVHDF is a feasible and well-
tolerated RRT in patients with cancer with ARF admitted to the 
ICU. Prognosis was comparable to previously published studies 
(Table 4). Detailed comparisons between studies are difficult due 
to different case-mix, indications and methods of RRT.
As expected, higher mortality was observed when hemato-
logical malignancies are considered (9). Two prognostic factors 
for hospital mortality were highlighted that could be helpful in 
selecting patients for CVVHDF with better chance to be hospital 
discharged. The increased number of organ failures has yet been 
found associated with a pejorative prognosis as well in cancer 
and general populations (7, 13, 15, 16, 20, 21). On the opposite, 
the role of hypoalbuminemia was more controversial in general 
ICU (22–25) but was not extensively assessed in patients with 
cancer. A negative effect on mortality of hypoalbuminemia 
was shown in one study and only in univariate analysis (16). 
It must be emphasized that the cancer characteristics (status, 
phase or treatment) were not predictors of hospital mortality. 
As previously reported, hospital mortality was linked to acute 
physiological changes induced by the complications leading to 
ICU admission while cancer variables influenced significantly 
survival after hospital discharge (18, 26, 27).
In addition to the effectiveness of CVVHDF in patients with 
cancer, this RRT showed also adequate tolerance in this frail 
population, often immunocompromised due to cancer or its 
treatment. This observation was rarely reported in the litera-
ture. Other authors assessing C-SLED (sustained low efficiency 
dialysis in the continuous mode) for RRT, reported complica-
tion due to hypocalcemia induced by citrate administration 
for anticoagulation (16). In another publication concerning 
hematological malignancies, no bleeding was observed despite 
severe thrombopenia and a catheter infection was documented 
in 5% of the patients (11). Patients and physicians need to 
know that a substantial number of RRT will lead to permanent 
chronic replacement therapy, despite the documented effec-
tiveness and tolerability of CVVHDF. In our study, 18% of the 
patients discharged alive from the hospital required a chronic 
dialysis. This was in the range between 14 and 24%, which is 
not different from rates observed in cancer patients (7, 13, 14) 
and in general ICU populations (28). It must be emphasized 
that in our study, five out of these seven patients presented with 
underlying renal diseases that could have contributed to the 
final renal status.
In the present study, we observed that half of the patients 
were exposed to a nephrotoxic drug that could have played a 
role in ARF development. Among them, anticancer drugs or 
immunosuppressive agents, the latter in case of bone marrow 
grafting, have been documented in 18% of the cases. A number 
of anticancer treatments are known for their nephrotoxicity with 
different pathophysiological mechanisms as cisplatin, nitrosou-
rea derivatives, mitomycin, ifosfamide, or methotrexate without 
being exhaustive. Different preventive methods as adequate 
hydration (cisplatin) or urine alkalinization (high dose metho-
trexate) are recommended. Clinicians have to be aware of the 
poor prognosis of ARF when prescribing potentially nephrotoxic 
chemotherapy in patient with disturbed renal function and/or at 
risk for ARF. They also have to consider the risk of ARF when 
administering nephrotoxic agents after a nephrotoxic chemo-
therapy as iodine contrast product and/or aminoglycoside after 
cisplatin administration.
Potential Bias and limitations
Some bias related to retrospective studies must be discussed. 
As  all the patients admitted to the ICU were prospectively 
recorded, a selection bias was unlikely. However, due to limited 
available data, some files have not been studied. The retrospec-
tive nature of our analysis could lead to missing data, which 
were minimal in our case. The number of patients in our study 
was limited but was in the same range as for the other publica-
tions. As   for other unicentric studies, generalization of the 
results is limited. Nevertheless, our results and conclusion are 
comparable to previous series suggesting adequate robustness 
of the data (13,  29). Multiple definitions for ARF have been 
proposed. In this retrospective study, we decided, based on 
available data, to apply a simple definition of ARF (an increase 
TaBle 4 | summary of publications assessing renal replacement therapy in patients with cancer admitted into icU.
reference Population N rrT Mortality Prognostic factors for hospital mortality
Mixed population (solid and hematological tumors, including bone marrow transplantation)
Berghmans et al. (15) Solid: 50% 32 CVVHDF ICU: 50% Number of organ failure
Hemato: 50% Hospital: 53%
BMT: 28%
Salahudeen et al. (5) Solid: 38% 199 C-SLED Day 30: 65% SOFA score, pH, mean blood pressure
Hemato: 62%
BMT: 18%
Mixed population (solid and hematological tumors, excluding bone marrow transplantation)
Maccariello et al. (13) Solid: 73% 118 IRRT daily conventional ICU: 70% Number of organ failure 
Hemato: 27% IRRT daily extended Hospital: 78%
CRRT
Darmon et al. (7) Solid: 7% 94 CRRT ICU: 43.6% LOD score, late RRT (>24 h after ICU 
admission)Hemato: 78% IRRT Hospital: 51.1%
Other: 15% 6 months: 65.4%
Soares et al. (14) Solid: 75% 98 IRRT conventional Hospital: 64–86% –
Hemato: 25% IRRT extended
CRRT
hematological tumors
Letourneau et al. (12) BMT: 100% 14 CVVHDF – –
IRRT
Lanore et al. (11) BMT: 11% 43 ICU: 72% ARF secondary to sepsis, SAPS score, 
mechanical ventilation support
Benoit et al. (9) BMT: 22.4% 50 IRRT ICU: 79.6% –
CRRT Hospital: 83.7%
6 months: 86%
Cancer series found by PubMed search using the MESH terms “Acute kidney injury” and “Intensive care.”
RRT, renal replacement therapy; CVVHDF, continuous venovenous hemodiafiltration; ICU, intensive care unit; C-SLED, sustained low efficiency dialysis in the continuous mode; 
CRRT, continuous renal replacement therapy; IRRT, intermittent renal replacement therapy; BMT, bone marrow transplantation; ARF, acute renal failure.
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of creatinine above 2 mg/dl). We did not use creatinine clearance 
or glomerular filtration rate because we were focusing on clinical 
settings where the clinicians decided performing RRT, most 
of the patients having high creatinine values and/or clinical 
signs of intolerance to ARF (acidosis, water overload …). Our 
data could deserve further prospective study in which a more 
precise definition of ARF should be used as RIFLE criteria or 
other clearance determination.
In conclusion, although ARF requiring RRT in patients with 
cancer admitted in ICU still has a poor prognosis, the use of 
CVVHDF is effective and tolerable in this immunocompromised 
population. Multiple organ failure and hypoalbuminemia have to 
be considered when deciding to introduce RRT in the treatment 
of this group of patients.
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